Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients

被引:0
|
作者
Michalowska-Wender, G
Losy, J
Wender, M
机构
[1] Polish Acad Sci, Neuroimmunol Unit, Med Res Ctr, PL-60355 Poznan, Poland
[2] Med Univ, Dept Neuroimmunol, Poznan, Poland
来源
FOLIA NEUROPATHOLOGICA | 2001年 / 39卷 / 01期
关键词
multiple sclerosis; immunological markers; cytokines; cerebrospinal fluid;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In patients suspected of multiple sclerosis (MS), even in the case of MRI positive changes, cerebrospinal fluid (CSF) analysis is of great practical value. Until now, however, only IgG index, restricted oligoclonal IgG bands and the examination of IgG subclasses have been of practical value. The determination of other immunological markers is too expensive to be introduced into laboratory diagnostic standards in MS. However, the clinical trials should be monitored by a large set of markers of MS activity, including the estimation of anti MBP antibodies, presence of MBP material in the CSF and concentration of sVCAM-1, ICAM-1, PECAM-1 in CSF and serum.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 50 条
  • [1] Biological markers for multiple sclerosis
    Lutterotti, Andreas
    Berger, Thomas
    Reindl, Markus
    CURRENT MEDICINAL CHEMISTRY, 2007, 14 (18) : 1956 - 1965
  • [2] Predictive markers to IFN β therapy in Multiple Sclerosis patients
    Charbit, H.
    Karussis, D.
    Petrou, P.
    Vaknin-Dembinsky, A.
    Lavon, I
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2013, 51 : S28 - S28
  • [3] The role of the psychologist in the diagnosis and therapy of multiple sclerosis patients
    Mielnik, Aleksandra
    AKTUALNOSCI NEUROLOGICZNE, 2018, 18 (01): : 27 - 33
  • [4] Predictive markers for response to interferon therapy in patients with multiple sclerosis
    Malucchi, S.
    Gilli, F.
    Caldano, M.
    Marnetto, F.
    Valentino, P.
    Granieri, L.
    Sala, A.
    Capobianco, M.
    Bertolotto, A.
    NEUROLOGY, 2008, 70 (13) : 1119 - 1127
  • [5] The use of biological markers in the diagnosis and follow-up of patients with multiple sclerosis.: Test of the five humours
    Oehninger-Gatti, C
    Buzó, R
    Alcántara, JC
    Chouza, C
    Gómez, A
    Cibils, D
    Gordon-Firing, S
    REVISTA DE NEUROLOGIA, 2000, 30 (10) : 977 - 979
  • [6] Biological markers of the inflammatory phase of multiple sclerosis
    Uccelli, A
    Pedemonte, E
    Narciso, E
    Mancardi, G
    NEUROLOGICAL SCIENCES, 2003, 24 (Suppl 5) : S271 - S274
  • [7] Biological markers of the inflammatory phase of multiple sclerosis
    A. Uccelli
    E. Pedemonte
    E. Narciso
    G. Mancardi
    Neurological Sciences, 2003, 24 : s271 - s274
  • [8] Body fluid markers to monitor multiple sclerosis: the assays and the challenges
    Laman, JD
    Thompson, EJ
    Kappos, L
    MULTIPLE SCLEROSIS JOURNAL, 1998, 4 (03) : 266 - 269
  • [9] Diagnosis and therapy for neurogenic bladder dysfunctions in multiple sclerosis patients
    Giulio Del Popolo
    Giovanni Panariello
    Francesca Del Corso
    Giuseppe De Scisciolo
    Giuseppe Lombardi
    Neurological Sciences, 2008, 29 : 352 - 355
  • [10] Predictive markers to interferon-beta therapy in multiple sclerosis patients
    Charbit, H.
    Geyshis, B.
    Karussis, D.
    Petrou, P.
    Smith, Y.
    Vaknin-Dembinsky, A.
    Lavon, I.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S232 - S233